Roswell Park appoints cell therapy specialist as senior vice president
Click Here to Manage Email Alerts
Marco Davila, MD, PhD, has been appointed senior vice president and associate director for translational research at Roswell Park Comprehensive Cancer Center.
Davila also will serve as vice chair for cellular therapies.
“What excites me most about joining Roswell Park is that they’ve already invested significant resources into being a site that can support the clinical investigation of homegrown and industry-sponsored cell therapies,” Davila said in a press release. “I’m really excited to have that opportunity to work with the cell-therapy teams, as well as the leadership at Roswell Park, to take advantage of these facilities and personnel to advance our gene and cell therapies and also work with biotechs, startups [and] pharmaceutical companies to bring these exciting therapies to the patients of Roswell Park.”
Davila previously served as senior member of the department of blood and marrow transplantation and director of the cell therapy facility at Moffitt Cancer Center.
When Davila was completing his residency and a fellowship at Memorial Sloan Kettering Cancer Center, he served as a clinical fellow on the team of Renier Brentjens, MD, PhD.
Davila worked with Brentjens — now deputy director at Roswell Park — to develop some of the first chimeric antigen receptor T-cell therapies to treat patients with hematologic malignancies.
“Dr. Davila is a gifted physician and a consummate translational scientist,” Brentjens said in the release. “He is highly attuned to his patients’ needs and priorities but also capable of great scientific imagination as he envisions new treatment strategies and designs the studies to develop them.”
Read more about
Click Here to Manage Email Alerts